Omeros Corporation (OMER)

Price$12.54

Favorite Metrics

Price vs S&P 500 (26W)175.06%

Price vs S&P 500 (4W)6.05%

Market Capitalization$895.99M

All Metrics

Book Value / Share (Quarterly)$0.33

P/TBV (Annual)3.46x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.62

Price vs S&P 500 (YTD)-31.32%

Gross Margin (TTM)98.75%

Net Profit Margin (TTM)-202.03%

EPS (TTM)$-0.26

10-Day Avg Trading Volume1.49M

EPS Excl Extra (TTM)$-0.26

EPS (Annual)$-2.71

ROI (Annual)8.98%

Gross Margin (Annual)98.78%

Net Profit Margin (5Y Avg)-185.94%

Cash / Share (Quarterly)$2.40

ROA (Last FY)-56.66%

EBITD / Share (TTM)$2.11

ROE (5Y Avg)111.99%

Operating Margin (TTM)-183.53%

Cash Flow / Share (Annual)$-1.62

P/B Ratio43.69x

P/B Ratio (Quarterly)16.66x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)17.96x

Net Interest Coverage (TTM)-4.67x

ROA (TTM)-1.41%

EV / EBITDA (TTM)9.57x

EPS Incl Extra (Annual)$-2.71

Current Ratio (Annual)2.76x

Quick Ratio (Quarterly)2.67x

3-Month Avg Trading Volume1.91M

52-Week Price Return75.25%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.03

P/S Ratio (Annual)12.14x

Asset Turnover (Annual)0.41x

52-Week High$17.65

Operating Margin (5Y Avg)-171.04%

EPS Excl Extra (Annual)$-2.71

CapEx CAGR (5Y)-25.33%

26-Week Price Return179.04%

Quick Ratio (Annual)2.67x

13-Week Price Return-4.45%

Total Debt / Equity (Annual)5.16x

Current Ratio (Quarterly)2.76x

Enterprise Value$1,281.02

Asset Turnover (TTM)0.45x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.72x

Pretax Margin (Annual)-203.39%

Cash / Share (Annual)$2.40

3-Month Return Std Dev61.03%

Gross Margin (5Y Avg)98.25%

Net Income / Employee (TTM)$-0

ROE (Last FY)55.34%

Net Interest Coverage (Annual)1.30x

EPS Basic Excl Extra (Annual)$-2.71

P/FCF (TTM)1.38x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)21.55x

EPS Incl Extra (TTM)$-0.26

Receivables Turnover (Annual)0.00x

ROI (TTM)11.65%

P/S Ratio (TTM)12.56x

Pretax Margin (5Y Avg)-197.82%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.03

Price vs S&P 500 (52W)45.42%

Year-to-Date Return-28.68%

5-Day Price Return2.85%

EPS Normalized (Annual)$-2.71

ROA (5Y Avg)-21.95%

Net Profit Margin (Annual)-187.13%

Month-to-Date Return16.00%

Cash Flow / Share (TTM)$-2.88

EBITD / Share (Annual)$-3.14

Operating Margin (Annual)-168.02%

LT Debt / Equity (Annual)4.04x

ROI (5Y Avg)-36.17%

LT Debt / Equity (Quarterly)16.70x

EPS Basic Excl Extra (TTM)$-0.26

P/TBV (Quarterly)3.46x

P/B Ratio (Annual)1.65x

Inventory Turnover (TTM)0.75x

Pretax Margin (TTM)-218.88%

Book Value / Share (Annual)$1.36

Price vs S&P 500 (13W)-5.13%

Beta2.59x

P/FCF (Annual)12.06x

Revenue / Share (TTM)$0.00

ROE (TTM)107.50%

52-Week Low$2.95

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.00

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
OMEROmeros Corporation	12.56x	—	98.75%	—	$12.54
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

Omeros is a clinical-stage biopharmaceutical company developing targeted therapies for complement-mediated diseases and immunologic disorders. The company's lead candidate, narsoplimab, is a monoclonal antibody in clinical trials for rare immune-related conditions including thrombotic microangiopathy following stem cell transplantation and immunoglobulin nephropathy. Omeros also has programs targeting cancer and additional large-market immunologic indications.